Lung cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• EGFR 300
• PD-L1 162
• PD-1 156
• KRAS 98
• ALK 72
• TP53 10
• HER2 63
• MET 43
• PI3K 1
• STAT3 0
• AKT 2
• ROS1 27
• mTOR 0
• VEGF 23
• BRAF 9
• RET 9
• NRF2 1
• MAPK 1
• ERK 0
• STING 0
• STK11 7
• YAP 1
• DLL3 27
• CTLA-4 15
• RAS 15
• CTNNB1 0
• TROP2 13
• JAK 1
• HIF-1 1
• AMPK 0
• PARP 2
• KEAP1 5
• JNK 0
• MYC 1
• B7-H3 14
• GPX4 0
• HER3 11
• PTEN 4
• MEK 1
• TIGIT 6
• FGFR 3
• IL-6 1
• PPAR 0
• EZH2 2
• HDAC 0
• PRMT5 7
• FAK 0
• COX-2 0
• HMGB1 0
• NTRK 5
• AXL 3
• BCL-2 0
• CDK4/6 4
• CXCR4 1
• CD47 1
• METTL3 0
• NLRP3 0
• SHP2 0
• HSP90 0
• MDM2 1

24 of 5,721 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Designing Programmable MOF-nanocomposites for Synergistic, Redox-Driven Antitumor Therapies (Photo-bioMOF)

  Fundacion IMDEA Energia· Mostoles Madrid, Spain· EU contribution €262,393· until Feb 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Identifying and disrupting neuroimmune circuits in cancer (NeuroCAN)

  Universitat Basel· Basel, Switzerland· EU contribution €1,874,590· until Jun 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting immunotherapy response in melanoma and non-small cell lung cancer patients using an extracellular vesicle-derived miRNA signature and a non-invasive CRISPR-based detection assay. (IT-PREDICT)

  Centre Georges-Francois Leclerc Association· Dijon, France· EU contribution €242,261· until Mar 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Dual Amplification Photoelectrochemical Platform for KRAS Mutation Detection (PEAKRAS)

  Universiteit Antwerpen· Antwerpen, Belgium· EU contribution €216,240· until Jan 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  KRAS Targeting in Oncogenic Systems: reconstructing the KRAS signalling network to identify optimal drug combinations (KRATOS)

  University College Dublin, National University of Ireland, Dublin· Dublin, Ireland· EU contribution €426,534· until Jan 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

5 of 66 running projects, newest first. Listed amounts together: €224.7m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

  NCT05642195· National Cancer Institute (NCI)· Updated 12 Nov 2026

  “Revisions to eligibility/design being made prior to enrollment of first participants.”Registry text, quoted unchanged. Source

• Suspended

  Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

  NCT06694454· National Cancer Institute (NCI)· Updated 12 Nov 2026

  “Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment.”Registry text, quoted unchanged. Source

• Suspended

  Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

  NCT04402788· National Cancer Institute (NCI)· Updated 12 Nov 2026

  “Scheduled Interim Monitoring”Registry text, quoted unchanged. Source

• Terminated

  Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

  NCT06083454· William Zeitler· Updated 10 Nov 2026

  “funding change”Registry text, quoted unchanged. Source

• Terminated

  Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

  NCT05353439· National Cancer Institute (NCI)· Updated 10 Nov 2026

  “Withdrawal of tazemetostat supply led to early study closure.”Registry text, quoted unchanged. Source

• Terminated

  Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

  NCT05132075· Novartis Pharmaceuticals· Updated 6 Nov 2026

  “Business reasons and not based on any safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  CT-95 in Advanced Cancers Associated With Mesothelin Expression

  NCT06756035· Context Therapeutics Inc.· Updated 5 Nov 2026

  “The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.”Registry text, quoted unchanged. Source

• Terminated

  A Nutritional Supplement to Support People With Non-small Cell Lung Cancer

  NCT04175769· AHS Cancer Control Alberta· Updated 3 Nov 2026

  “Unreliable supply of investigational product.”Registry text, quoted unchanged. Source

• Withdrawn

  Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

  NCT07353957· Genmab· Updated 2 Nov 2026

  “This study-level decision was based on the evolving treatment landscape and strategic portfolio considerations and is not related to any safety concern.”Registry text, quoted unchanged. Source

• Suspended

  HEARTS Trial for Thoracic Cancers

  NCT07132918· University of Wisconsin, Madison· Updated 30 Oct 2026

  “Funding issues”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

  NCT04665739· National Cancer Institute (NCI)· Source

• DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

  NCT07707895· Boehringer Ingelheim· Source

• STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma

  NCT07902921· National Cancer Institute (NCI)· Source

• Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

  NCT04310020· National Cancer Institute (NCI)· Source

• Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

  NCT01950572· National Cancer Institute (NCI)· Source

• Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT03088540· Regeneron Pharmaceuticals· Source

• Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

  NCT05198830· National Cancer Institute (NCI)· Source

• Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

  NCT03793179· National Cancer Institute (NCI)· Source

• Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  NCT06498635· National Cancer Institute (NCI)· Source

• National Cancer Institute "Cancer Moonshot Biobank"

  NCT04314401· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 145
• Organoids 47
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 43
• Gene Expression Profiling 314
• Sequence Analysis, RNA 43
• Whole Genome Sequencing 13
• Exome Sequencing 18
• Proteomics 133
• Metabolomics 67
• Mass Spectrometry 25
• Flow Cytometry 73
• Immunohistochemistry 191
• Liquid Biopsy 76
• Circulating Tumor DNA 83
• Xenograft Model Antitumor Assays 617
• Positron-Emission Tomography 70
• Magnetic Resonance Imaging 116
• Machine Learning 290
• Deep Learning 211
• Cohort Studies 289
• Genome-Wide Association Study 75

• Altered resting-state functional connectivity in lung cancer patients with comorbid depressive symptoms.

  Support Care Cancer, Oct 2026

• MRI-based intratumoral and peritumoral heterogeneity for predicting intracranial progression in EGFR-mutant lung adenocarcinoma patients with treatment-naive brain metastases receiving first-line third-generation EGFR-TKIs.

  J Transl Med, Oct 2026

• THINKERS-X: multisequence MRI radiomics in a mixture-of-experts model for outcome prediction and exploratory dose-scenario evaluation in lung cancer brain metastases treated with radiosurgery.

  Clin Exp Metastasis, Oct 2026

• Metastatic muscle invasive bladder cancer in pregnancy.

  BMJ Case Rep, Sept 2026

• [Application and Future Prospects of Magnetic Resonance-Guided Adaptive Radiotherapy in Lung Cancer Treatment].

  Zhongguo Yi Liao Qi Xie Za Zhi, Sept 2026

• Radiomics and deep learning for immune checkpoint inhibitor outcomes: imaging-derived immune phenotyping and clinical translation across solid tumors.

  Front Immunol, Sept 2026

• Cerebral Amyloid Angiopathy-Related Inflammation Mimicking Leptomeningeal Metastasis After Resected Lung Adenocarcinoma: A Case Report Highlighting Dynamic Diagnostic Reassessment.

  Curr Oncol, Sept 2026

• Early detection of invasive lung cancer and multiorgan metastasis by a collagen-targeted protein MRI contrast agent.

  Sci Adv, Sept 2026

• Prophylactic cranial irradiation versus active MRI surveillance for limited-stage small-cell lung cancer achieving response after chemoradiotherapy: a protocol for a randomized, controlled, multicenter, phase III trial.

  Respir Res, Sept 2026

• Extensive cervical myelitis following pembrolizumab treatment after prior radiotherapy: a case report.

  Swiss Med Wkly, Aug 2026

See which targets of this disease your abstract mentions, and go to the people working on them.